Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ADIL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| AD04 (ondansetron) | Alcohol Use Disorder | Phase 3 · NCT04101227 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ADIL holds $28.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $4M/quarter from operations, an estimated runway of 21.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 38 · Moderate
After evaluating the conditions described above in the aggregate, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADIL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Coastlands Capital LP 10% owner |
Insider | 388,308 | 14.79% | 2026-07-14 |
| Matt Davidson Chief Development Officer, Director · +232,417 options |
Insider | 300,918 | 11.46% | 2026-06-11 |
| Cary J Claiborne Chief Executive Officer, Director · +548,000 options |
Insider | 40,417 | 1.54% | 2026-04-07 |
| Tony Goodman Chief Operating Officer, Director · +136,000 options |
Insider | 26,523 | 1.01% | 2026-04-07 |
| Vinay Shah Chief Financial Officer · +49,000 options |
Insider | 17,325 | 0.66% | 2026-04-07 |
| Kevin Schuyler Director · +40,000 options |
Insider | 9,447 | 0.36% | 2026-04-07 |
| Robertson H. Gilliland Director · +40,000 options |
Insider | 9,185 | 0.35% | 2026-04-07 |
Share count 2,625,890 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADIL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →